Latanoprost in the treatment of glaucoma

QR Code

Latanoprost in the treatment of glaucoma

Albert AlmDepartment of Neuroscience, Ophthalmology, University Hospital, Uppsala, SwedenAbstract: Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Alm A
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2014
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/4828795329a441158138cffbf848d394
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
par: Pacella F, et autres
Publié: (2012)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
par: Andrea Russo, et autres
Publié: (2009)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
par: Sacchi M, et autres
Publié: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
par: Yoshimi Nakamura, et autres
Publié: (2009)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
par: Antoine Lafuma, et autres
Publié: (2011)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
par: Gutierrez-Diaz E, et autres
Publié: (2014)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
par: Gregory Katz, et autres
Publié: (2010)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
par: Bhagat P, et autres
Publié: (2014)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
par: Edmund P Farris
Publié: (2008)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
par: Myers JS, et autres
Publié: (2014)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
par: Makoto Ishikawa, et autres
Publié: (2009)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
par: Yelda Buyru &Ouml;zkurt, et autres
Publié: (2009)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
par: Maruyama Y, et autres
Publié: (2015)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
par: David A Godfrey, et autres
Publié: (2009)

Prostaglandin-associated periorbitopathy in latanoprost users
par: Nakakura S, et autres
Publié: (2014)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
par: Inoue K, et autres
Publié: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
par: Michael J Miyashiro, et autres
Publié: (2010)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
par: Muñoz Negrete FJ, et autres
Publié: (2017)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
par: Kanamoto T, et autres
Publié: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
par: Douglas J Rhee, et autres
Publié: (2008)

Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study
par: Shusaku Ishikawa, et autres
Publié: (2008)

Characteristics of uveitic glaucoma and evaluation of its surgical treatment
par: Shimizu A, et autres
Publié: (2014)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
par: Ikeda Y, et autres
Publié: (2016)

An emerging treatment option for glaucoma: Rho kinase inhibitors
par: Wang SK, et autres
Publié: (2014)

Mirtogenol&reg; potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
par: Robert D Steigerwalt Jr, et autres
Publié: (2010)

Long-term safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma
par: Tarek A Shazly, et autres
Publié: (2010)

Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
par: Fechtner RD, et autres
Publié: (2011)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
par: Inoue K, et autres
Publié: (2013)

Current primary open-angle glaucoma treatments and future directions
par: Beidoe G, et autres
Publié: (2012)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
par: Jordana K Schmier, et autres
Publié: (2010)

Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma
par: Marey HM, et autres
Publié: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
par: Lanzl I, et autres
Publié: (2013)

Does the type of treatment have an influence on utility values in a glaucoma population?
par: Paletta Guedes RA, et autres
Publié: (2015)

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
par: Canut MI, et autres
Publié: (2011)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
par: E Randy Craven, et autres
Publié: (2010)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
par: Beck DER, et autres
Publié: (2017)

Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma
par: Christopher C Shen, et autres
Publié: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
par: Inoue K, et autres
Publié: (2014)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
par: Inoue K, et autres
Publié: (2012)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
par: Ermiş&nbsp;SS
Publié: (2012)